Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540223 | 0.85 | IDO1 (0.40) | IDO1KMT2AMAOBMMP12MMP1 | |
| SCHEMBL2095615 | 0.81 | TAAR1 (0.50) | IDO1KMT2AMAOBTAAR1MIF | |
| SCHEMBL3365902 | 0.80 | APP (0.47) | KMT2ANAAA | |
| SCHEMBL2096262 | 0.80 | IDO1 (0.57) | IDO1 | |
| SCHEMBL2087029 | 0.78 | IDO1 (0.62) | IDO1MAOBTAAR1MMP12MMP1 | |
| SCHEMBL2096837 | 0.78 | TAAR1 (0.47) | IDO1KMT2AMAOBTAAR1NAAA | |
| SCHEMBL514457 | 0.77 | GPR84 (0.42) | MMP1 | |
| SCHEMBL95538 | 0.77 | IDO1 (0.52) | IDO1MAOBTAAR1 | |
| SCHEMBL5536424 | 0.77 | HDAC1 (0.49) | IDO1KMT2AMAOBTAAR1NAAA | |
| SCHEMBL492736 | 0.76 | IDO1 (0.68) | IDO1KMT2AMAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396296-A | Preparation method of ertapenem | 武汉瑞晟药业有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| WO-2009032840-A1 | FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20070161634-A1 | Compounds as CCR5 antagonists | SHANGHAI TARGET DRUG CO., LTD. (CN) | 2007-07-12 | — | — | US | claimed |
| EP-1760079-A1 | COMPOUNDS AS COR5 ANTAGONISTS | Shanghai Target Drug Co., Ltd. (CN) | 2007-03-07 | — | — | EP | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| CN-115232117-B | Substituted isoxazole pyrimidine amine compound, preparation method and application thereof | 沈阳中化农药化工研发有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-107778298-B | Pyrimidine-containing substituted azole compound and application thereof | 沈阳中化农药化工研发有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111004218-B | Pyrimidine compound containing piperidine and application thereof | 沈阳中化农药化工研发有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116396296-A | Preparation method of ertapenem | 武汉瑞晟药业有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-110964037-B | Pyrimidine-fused ring-containing compound and preparation method and application thereof | 沈阳中化农药化工研发有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-3760617-B1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2023-03-22 | — | — | EP | disclosed |
| WO-1992006998-A1 | CYCLOPEPTIDES, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1992-04-30 | — | — | WO | disclosed |
| US-5017573-A | Serotonin receptor antagonist | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0358903-A2 | Indazole-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1990-03-21 | — | — | EP | disclosed |
| US-4500709-A | INTERMEDIATES IN THE PREPARATION OF CEPHALOSPORIN COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-02-19 | — | — | US | disclosed |
| US-4371531-A | OXIME-SUBSTITUTED ANTIBIOTICS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1983-02-01 | — | — | US | disclosed |
| US-4242510-A | Cephalosporin compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | IDO1 3181/4885KMT2A 4267/4885MAOB 2140/4885 |
| US-20070161634-A1 | Compounds as CCR5 antagonists | CCR5, CXCR3, CCL5 | IDO1 257/4885KMT2A 4577/4885MAOB 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.